It's been more than two decades since Doxil (doxorubicin, Johnson & Johnson), a liposome-based chemotherapy, was approved by the FDA. During that time, the field has evolved from simply protecting other tissue from highly potent drugs until they get to the site of the disease to increasing targeting and bioavailability.
It's been more than two decades since Doxil (doxorubicin, Johnson & Johnson), a liposome-based chemotherapy, was approved by the FDA. During that time, the field has evolved from simply protecting other tissue from highly potent drugs until they get to the site of the disease to increasing targeting and bioavailability.
The quest to get the first drug approved to treat fragile X is heating up with three companies – Tetra Discovery Partners Inc., Zynerba Pharmaceuticals Inc. and Ovid Therapeutics Inc. – starting clinical trials this month.
Approved in late 2016, Spinraza (nusinersen) remains the only drug cleared to treat spinal muscular atrophy (SMA), but multiple companies are looking to grab a share of the blockbuster market established by Cambridge, Mass.-based Biogen Inc. and its development partner, Ionis Pharmaceuticals Inc., of Carlsbad, Calif.
Backed with an upsized $85 million series C financing, Sutrovax Inc. is looking to supplant New York-based Pfizer Inc.'s Prevnar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) as the go-to vaccine protecting against Streptococcus pneumonia infection in the $6 billion annual market.
At the World Federation of Hemophilia (WFH) 2018 World Congress, the old and new guard of companies developing hemophilia treatments presented their plans to change the market.
For new drug classes, there’s often the easiest way and the best way. The former often wins in the short term, but the best way will end up being superior – as long as technology can overcome the obstacles.
